As we already know from media reports and hedge fund investor letters, many hedge funds lost money in the third quarter, blaming macroeconomic conditions and unpredictable events...
Keep Reading →
December 2 - Hedge Funds, News - Comments
Founded in 1987, Apex Capital Management invests mainly in companies that have market caps of up to $10 billion and is currently overseeing $6.5 billion in assets under management...
Keep Reading →
October 28 - Hedge Funds, News - Comments
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) appears to be trending in the right direction again after a sharp decline earlier this year.
Keep Reading →
September 12 - Market Movers, News - Comments
Biotech bets. The first thing to know about Citadel and Ken Griffin is that they typically employ a high level of portfolio turnover on a quarterly basis.
Keep Reading →
November 15 - Hedge Funds, News - Comments
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), a developer and marketer of RNA-based novel drugs to treat a variety of diseases, has been one of the best performing stocks in the ...
Keep Reading →
September 20 - News - Comments
Big Pharma gets plenty of hype.
Keep Reading →
September 17 - News - Comments
With all of the heat generated by this biotech and its stock, it pays to pay attention to what Celgene Corporation (NASDAQ:CELG) says.
Keep Reading →
September 16 - News - Comments
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
September 15 - News - Comments
For the latest deal, Biogen Idec Inc (NASDAQ:BIIB) is giving Isis $100 million up front, and ISIS Pharmaceuticals, Inc.
Keep Reading →
September 11 - News - Comments
I know it's like comparing apples and oranges, but humor me for a moment.
Keep Reading →
September 11 - News - Comments
The last several months have been remarkably exciting in the biotech space.
Keep Reading →
September 11 - News - Comments
Make that four collaborations between Biogen Idec Inc. (NASDAQ:BIIB) and ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) in the last two years.
Keep Reading →
September 10 - News - Comments
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 9 - News - Comments
In the eyes of many investors, hedge funds are perceived as bloated, outdated financial vehicles of a forgotten age.
Keep Reading →
August 28 - News - Comments
In the financial world, there are many metrics shareholders can use to track their holdings. A duo of the most innovative are hedge fund and insider trading movement.
Keep Reading →
August 23 - News - Comments
It has been approximately a year since the Citron Research report about Questcor Pharmaceuticals Inc (NASDAQ:QCOR) came out, which caused the stock to lose more than half of its...
Keep Reading →
August 21 - News - Comments
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 12 - News - Comments
The Motley Fool's readers have spoken, and I have heeded their cries.
Keep Reading →
August 7 - News - Comments
As human beings it can sometimes be difficult for us to see the good in a bad situation.
Keep Reading →
August 7 - News - Comments
Both ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) and Aegerion Pharmaceuticals, Inc.
Keep Reading →
August 5 - News - Comments
The US pharmaceutical industry has been revolutionized by the emerging biotech companies which have discovered new ways to cure even the rarest of diseases.
Keep Reading →
August 1 - News - Comments
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
August 1 - News - Comments
RNAi and RNA companies had a terrible time when they were abandoned by big pharmaceutical companies.
Keep Reading →
July 10 - News - Comments
Imagine finding out that you have a disease that only a handful of people around the world have. Kirstie and Catherine Fields don't have to imagine it.
Keep Reading →
July 5 - News - Comments
It's hard to believe, but 2013 is already more than halfway over. This year has been a good one for many pharmaceutical stocks -- at least so far.
Keep Reading →
July 3 - News - Comments
In the last couple of years, the biotechnology industry has been on a roll.
Keep Reading →
July 2 - News - Comments
Biotech companies sometimes get lucky, launching a drug into a new indication where there's no competition, but more often than not the biotech companies have to battle it out...
Keep Reading →
June 27 - News - Comments
With the markets under pressure, we are beginning to see more downgrades and fewer upgrades.
Keep Reading →
June 27 - News - Comments
Is ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) worth your attention right now? Investors who are in the know are taking an optimistic view.
Keep Reading →
June 4 - News - Comments
If you'd owned these three biotech companies at the beginning of the year, you're sitting on around a triple compared to a relatively smaller-but-still-impressive 34% increase...
Keep Reading →
June 3 - News - Comments
At the moment, there are a multitude of metrics investors can use to analyze their holdings. A duo of the most under-the-radar are hedge fund and insider trading activity.
Keep Reading →
May 31 - News - Comments
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
May 29 - News - Comments
Wall Street had a great week. The Dow topped 15,000. The S&P 500 also notched a record high. But few stocks blew the doors off like those of these three biotech companies.
Keep Reading →
May 4 - News - Comments
Amgen, Inc. (NASDAQ:AMGN) stock has been on a bit of a roller coaster lately.
Keep Reading →
May 1 - News - Comments
Within the next few days, stocks for two orphan drugmakers could either soar or sink. Both Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Raptor Pharmaceutical Corp.
Keep Reading →
April 24 - News - Comments
Yesterday we looked at the first part of my attempt to parallel the similarities between one of America's most-watched sports, auto racing (i.e., NASCAR), and investing.
Keep Reading →
April 21 - News - Comments
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) was in 5 hedge funds' portfolio at the end of December.
Keep Reading →
April 19 - News - Comments
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Keep Reading →
April 16 - News - Comments
Roche Holding Ltd. (ADR) (PINK:RHHBY) and ISIS Pharmaceuticals, Inc.
Keep Reading →
April 8 - News - Comments
It's been quite a while since we had a big wedding in the pharma world.
Keep Reading →
March 28 - News - Comments
The stock market is stuck in a waiting game as investors wait for a resolution to the Cypriot banking crisis. In the meantime, the U.S.
Keep Reading →
March 21 - News - Comments
I have reviewed over 80 stocks as investment opportunities.
Keep Reading →
March 6 - News - Comments
On Monday, Depomed Inc (NASDAQ:DEPO) is expected to go before the FDA panel with its menopausal hot-flash drug, Serada.
Keep Reading →
March 4 - News - Comments
Orphan drugs -- medications meant for small patient populations with rare, dangerous diseases -- can be a rewarding business for biotech firms that strike gold.
Keep Reading →
February 22 - News - Comments
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) started the year strong with a Food and Drug Administration approval for genetic high cholesterol drug Kynamro.
Keep Reading →
February 19 - News - Comments
I was admittedly never very good when it came to limbo because I'm not very flexible and I'm all legs. Sanofi SA (ADR) (NYSE:SNY) and ISIS Pharmaceuticals, Inc.
Keep Reading →
February 5 - News - Comments
